Amylyx Pharmaceuticals, Inc.
AMLX
Clasificación en acciones
#4491
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Precio por acción
$27.25
Última sincronización: 2026-10-19
Capitalización bursátil
$3.42B
Cambio (1 día)
3.45%
Cambio (1 año)
77.29%
País
US
Comercio Amylyx Pharmaceuticals, Inc. (AMLX)
Categoría
Healthcare
Ratio P/S de Amylyx Pharmaceuticals, Inc. (AMLX)
Ratio P/S al October 2026 TTM: 0.00
Según los informes financieros más recientes y el precio de las acciones de Amylyx Pharmaceuticals, Inc., el ratio P/S actual (TTM) es 0.00. Al final de 2023, el ratio P/S era 2.60.
Historial del ratio P/S de Amylyx Pharmaceuticals, Inc. desde 2019 hasta 2026
Ratio P/S al final de cada año
| Año | Ratio P/S | Cambiar |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 2.95 | 13.43% |
| 2023 | 2.60 | -97.65% |
| 2022 | 110.55 | -96.99% |
| 2021 | 3.67K | 133.72% |
| 2020 | 1.57K | 119.38% |
| 2019 | 715.53 | 0.00% |
Ratio P/S de empresas similares o competidoras
| Empresa | Ratio P/S | Diferencia del ratio P/S | País |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
